Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 31

1.

Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.

Thrasher J.

Am J Cardiol. 2017 Jul 1;120(1S):S4-S16. doi: 10.1016/j.amjcard.2017.05.009. Epub 2017 May 30. Review.

2.

Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.

Paneni F, Lüscher TF.

Am J Cardiol. 2017 Jul 1;120(1S):S17-S27. doi: 10.1016/j.amjcard.2017.05.015. Epub 2017 May 30. Review.

3.

Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.

Paneni F, Lüscher TF.

Am J Med. 2017 Jun;130(6S):S18-S29. doi: 10.1016/j.amjmed.2017.04.008. Review.

4.

Cardiovascular events associated with second-line anti-diabetes treatments: analysis of real-world Korean data.

Ha KH, Kim B, Choi H, Kim DJ, Kim HC.

Diabet Med. 2017 Sep;34(9):1235-1243. doi: 10.1111/dme.13384. Epub 2017 Jun 5.

PMID:
28523719
5.

Comparative cardiovascular risks of dipeptidyl peptidase 4 inhibitors with other second- and third-line antidiabetic drugs in patients with type 2 diabetes.

Ou HT, Chang KC, Li CY, Wu JS.

Br J Clin Pharmacol. 2017 Jul;83(7):1556-1570. doi: 10.1111/bcp.13241. Epub 2017 Feb 27.

PMID:
28109184
6.
7.

Comparative risk for cardiovascular diseases of dipeptidyl peptidase-4 inhibitors vs. sulfonylureas in combination with metformin: Results of a two-phase study.

Enders D, Kollhorst B, Engel S, Linder R, Verheyen F, Pigeot I.

J Diabetes Complications. 2016 Sep-Oct;30(7):1339-46. doi: 10.1016/j.jdiacomp.2016.05.015. Epub 2016 May 20.

PMID:
27245402
8.

Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records.

Zghebi SS, Steinke DT, Rutter MK, Emsley RA, Ashcroft DM.

Diabetes Obes Metab. 2016 Sep;18(9):916-24. doi: 10.1111/dom.12692. Epub 2016 Jun 30.

PMID:
27177784
10.

Refitting of the UKPDS 68 risk equations to contemporary routine clinical practice data in the UK.

McEwan P, Bennett H, Ward T, Bergenheim K.

Pharmacoeconomics. 2015 Feb;33(2):149-61. doi: 10.1007/s40273-014-0225-z.

PMID:
25344660
11.

Combination therapy with metformin plus sulphonylureas versus metformin plus DPP-4 inhibitors: association with major adverse cardiovascular events and all-cause mortality.

Morgan CL, Mukherjee J, Jenkins-Jones S, Holden SE, Currie CJ.

Diabetes Obes Metab. 2014 Oct;16(10):977-83. doi: 10.1111/dom.12306. Epub 2014 May 22.

PMID:
24762119
12.

A systematic review of acute pancreatitis as an adverse event of type 2 diabetes drugs: from hard facts to a balanced position.

Giorda CB, Nada E, Tartaglino B, Marafetti L, Gnavi R.

Diabetes Obes Metab. 2014 Nov;16(11):1041-7. doi: 10.1111/dom.12297. Epub 2014 Apr 29. Review.

PMID:
24702687
13.

Safety and efficacy of gliclazide as treatment for type 2 diabetes: a systematic review and meta-analysis of randomized trials.

Landman GW, de Bock GH, van Hateren KJ, van Dijk PR, Groenier KH, Gans RO, Houweling ST, Bilo HJ, Kleefstra N.

PLoS One. 2014 Feb 12;9(2):e82880. doi: 10.1371/journal.pone.0082880. eCollection 2014. Review.

14.

Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitor.

Nicolle LE, Capuano G, Fung A, Usiskin K.

Postgrad Med. 2014 Jan;126(1):7-17. doi: 10.3810/pgm.2014.01.2720.

PMID:
24393747
15.

Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease.

Green JB, Bethel MA, Paul SK, Ring A, Kaufman KD, Shapiro DR, Califf RM, Holman RR.

Am Heart J. 2013 Dec;166(6):983-989.e7. doi: 10.1016/j.ahj.2013.09.003. Epub 2013 Oct 23.

PMID:
24268212
16.

Association of hypoglycemic treatment regimens with cardiovascular outcomes in overweight and obese subjects with type 2 diabetes: a substudy of the SCOUT trial.

Ghotbi AA, Køber L, Finer N, James WP, Sharma AM, Caterson I, Coutinho W, Van Gaal LF, Torp-Pedersen C, Andersson C.

Diabetes Care. 2013 Nov;36(11):3746-53. doi: 10.2337/dc13-0027. Epub 2013 Oct 2.

17.
18.

Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis.

Phung OJ, Schwartzman E, Allen RW, Engel SS, Rajpathak SN.

Diabet Med. 2013 Oct;30(10):1160-71. doi: 10.1111/dme.12232. Review.

PMID:
23663156
19.
20.

Evolution of exenatide as a diabetes therapeutic.

Bhavsar S, Mudaliar S, Cherrington A.

Curr Diabetes Rev. 2013 Mar 1;9(2):161-93. Review.

Supplemental Content

Loading ...
Support Center